1007882-05-4

Basic information

• Product Name: C₁₈H₂₀BrF₂N₃O₂
• Synonyms: C₁₈H₂₀BrF₂N₃O₂
• CAS NO: 1007882-05-4
• Molecular Weight: 428.277
• Mol File: 1007882-05-4.mol
• Article Data: 16

Chemical Properties

• CAS DataBase Reference: C₁₈H₂₀BrF₂N₃O₂(CAS DataBase Reference)
• NIST Chemistry Reference: C₁₈H₂₀BrF₂N₃O₂(1007882-05-4)
• EPA Substance Registry System: C₁₈H₂₀BrF₂N₃O₂(1007882-05-4)

Safety Data

• Hazardous Substances Data: 1007882-05-4(Hazardous Substances Data)

Upstream product

• 1612854-21-3 C₁₈H₂₀BrF₂NO₅ 
• 203866-15-3 1-(tert-butoxycarbonyl)-4,4-difluoro-L-proline 
• 203866-17-5 1-tert-butyl 2-methyl (2S)-4,4-difluoropyrrolidine-1,2-dicarboxylate 
• 102195-80-2 (S)-1-tert-butyl 2-methyl 4-oxopyrrolidine-1,2-dicarboxylate 
• 74844-91-0 (2S,4S)-N-tert-butoxycarbonyl-4-hydroxyproline methyl ester 
• 1007881-99-3 (S)-tert-butyl 2-(2-(4-bromophenyl)-2-oxoethylcarbamoyl)-4,4-difluoropyrrolidine-1-carboxylate 

Downstream Products

• 1399843-28-7 methyl ((S)-1-((S)-4,4-difluoro-2-(5-(4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenyl)-1H-imidazol-2-yl)pyrrolidin-1-yl)-3-methyl-1-oxobutan-2-yl)carbamate 
• 1430061-55-4 {(4S,7S)-4-[5-(4'-{2-[(S)-4,4-difluoro-1-((S)-2-methoxycarbonylamino-3-methylbutyryl)pyrrolidin-2-yl]-3H-imidazol-4-yl}biphenyl-4-yl)-1H-imidazol-2-yl]-6,10-dioxooctahydropyridazino[1,2-a][1,2]diazepin-7-yl}carbamic acid methyl ester 
• 1399843-30-1 methyl ((S)-1-((S)-2-(5-(4-bromophenyl)-1H-imidazol-2-yl)-4,4-difluoropyrrolidin-1-yl)-3-methyl-1-oxobutan-2-yl)carbamate 
• 1560643-26-6 C₃₀H₃₀F₅N₃O₅S 
• 1560643-28-8 C₃₅H₄₂BF₂N₃O₄ 
• 1560643-31-3 C₄₁H₄₆F₄N₆O₄ 
• 1560638-96-1 C₄₅H₅₂F₄N₈O₆ 
• 1007882-13-4 C₂₄H₃₂BF₂N₃O₄ 
• 1613055-67-6 C₃₀H₃₀F₅N₃O₅S 
• 1612854-23-5 C₃₄H₃₇F₅N₄O₇S 
• 1399843-28-7 C₂₆H₃₅BF₂N₄O₅ 
• 1612854-22-4 C₁₉H₂₄BF₂N₃O₂ 
• 1334312-52-5 MK-8325 
• 1007882-13-4 (S)-tert-butyl 4,4-difluoro-2-(5-(4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenyl)-1H-imidazol-2-yl)pyrrolidine-1-carboxylate 

Relevant articles and documents

As hepatitis c inhibitor spiro compound and its use in medicine

The invention provides a spiro compound serving as a hepatitis c inhibitor and application thereof in a medicine. The compound is a compound as shown in a formula (I) or a stereisomer, a geometric isomer, a tautomer, nitric oxide, an aquo-complex, a solvate, a metabolite, pharmaceutically acceptable salt or prodrug of the compound as shown in the formula (I). The invention also provides a pharmaceutical composition containing the compound, application of the compound and the pharmaceutical composition in inhibition of HCV (Hepatitis C Virus) copy and HCV virus protein, as well as the application of the compound and the pharmaceutical composition in prevention, handling, treatment or relieving of HCV infection or hepatitis c disease for a patient. The formula I is as shown in the specification.

FUSED TRICYCLIC SILYL COMPOUNDS AND METHODS OF USE THEREOF FOR THE TREATMENT OF VIRAL DISEASES

no abstract published

SPIRO RING COMPOUND AS HEPATITIS C VIRUS (HCV) INHIBITOR AND USES THEREOF FIELD OF THE INVENTION

A compound of formula (I) or a stereoisomer, a geometric isomer. a tautomer, an N-oxide, a hydrate, a solvate, a metabolite, a pharmaceutically acceptable salt or a prodrug thereof is provided, which can be used for treating HCV infection or a HCV disorder. Also a pharmaceutical composition comprising the compound and the use of the compound and the pharmaceutical composition thereof are provided, which can also be used for treating HCV infection or a HCV disorder.